

Frailty-adjusted therapy in transplant non-eligible patients with newly diagnosed multiple myeloma

Submission date 27/11/2020	Recruitment status No longer recruiting	☐ Prospectively registered ☒ Protocol
Registration date 18/01/2021	Overall study status Ongoing	☐ Statistical analysis plan ☐ Results
Last Edited 04/03/2024	Condition category Cancer	☐ Individual participant data ☐ Record updated in last year

Plain English summary of protocol

<https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-ixazomib-lenalidomide-and-dexamethasone-for-people-with-myeloma-fitness>

Background and study aims

Myeloma is a type of bone marrow cancer diagnosed in around 5500 patients in the UK each year. The development of treatments has increased life expectancy in all patients, but these have been less effective in older and frailer patients. There is no evidence to suggest their myeloma is more aggressive, so it needs to be asked why this is the case. Research is beginning to look at older myeloma patients who are ineligible for transplants. Myeloma XI, a previous trial where 1840 of these patients were recruited, has shown that treatment outcomes were not necessarily associated with different combinations of treatment. The aim of this study is to compare standard and frailty-adjusted induction treatment with ixazomib, lenalidomide and dexamethasone and maintenance lenalidomide to lenalidomide plus ixazomib.

Who can participate?

Newly diagnosed myeloma patients, above the age of 18, who are not eligible for a stem cell transplant

What does the study involve?

All participants receive induction treatment with ixazomib, lenalidomide and dexamethasone and are randomly allocated to either frailty score-adjusted treatment or standard upfront treatment followed by toxicity-dependent dose modifications during treatment. Following 12 cycles of induction treatment participants alive and progression-free undergo a second randomisation. In the second phase of the trial, patients will be tested to assess whether lenalidomide and ixazomib are effective as a maintenance treatment. Patients will either receive lenalidomide and ixazomib, or lenalidomide and placebo (something that has a similar taste and appearance to ixazomib but has no effect on the person) to test this.

What are the possible benefits and risks of participating?

Evidence from previous trials has shown that patients who are older and living with other health

issues do not stay on standard treatment for as long as younger, fitter patients. This study will explore whether tailoring the medication will increase the durability of treatment in older patients to ensure a longer benefit and therefore reduce the risk of having to stop treatment early due to side effects. Participants will be helping to answer important questions and it is hoped that this will improve treatment now and for future patients.

At the moment, neither the IRD induction treatment nor maintenance therapy with either lenalidomide alone or in combination with ixazomib is available on the NHS for the treatment of newly diagnosed myeloma, and so this study gives access to these treatments. Previous studies have shown that maintenance therapy with lenalidomide can increase the length of disease remission. The goal of this study is to gain a greater understanding of the various treatment options available for myeloma patients, how they compare to each other and how they are best delivered to patients. This may or may not be a better approach to treating myeloma compared to what doctors do currently.

There are potential risks associated with the study as well as potential side effects from the trial treatments and drugs. A small number of patients may develop additional types of cancer, and it is possible that this risk may be increased with lenalidomide treatment. Some medications, and complementary health supplements such as St John's Wort, should not be used during this study as they may interact with the study medications.

Patients who take part in this study are potentially at risk of becoming sterile or infertile. This is also the case with other chemotherapy treatments participants would likely receive if they were not on the study. If appropriate, counselling and a referral for fertility assessment and preservation will be available. Some patients with myeloma find that they can continue to work during treatment.

Where is the study run from?
University of Leeds (UK)

When is the study starting and how long is it expected to run for?
August 2017 to August 2027

Who is funding the study?
The study is largely funded by Cancer Research UK. Some of the costs of the drugs being used in the study, as well as some additional funding for the running of the study, is being provided by the companies who make two of the drugs being investigated, Takeda (ixazomib) and Celgene (lenalidomide).

Who is the main contact?
Rowena Henderson
ctr_u_myelomaxiv@leeds.ac.uk

Contact information

Type(s)
Scientific

Contact name
Ms Rowena Henderson

Contact details
Leeds Institute of Clinical Trials Research
Clinical Trials Research Unit

University of Leeds
Leeds
United Kingdom
LS2 9JT
+44 (0)113 343 1159
ctru_myelomaxiv@leeds.ac.uk

Type(s)

Public

Contact name

Ms Sharon Gillson

Contact details

Leeds Institute of Clinical Trials Research
Clinical Trials Research Unit
University of Leeds
Leeds
United Kingdom
LS2 9JT
+44 (0)113 34 39368
ctru_myelomaxiv@leeds.ac.uk

Additional identifiers

ClinicalTrials.gov (NCT)

NCT03720041

Clinical Trials Information System (CTIS)

2018-003590-10

Integrated Research Application System (IRAS)

234453

Protocol serial number

Version 2.0, 10th October 2019

Study information

Scientific Title

A phase III trial to compare standard and frailty-adjusted induction therapy with ixazomib, lenalidomide and dexamethasone (IRD) and maintenance lenalidomide (R) to lenalidomide plus ixazomib (IR)

Acronym

FiTNEss (UK-MRA Myeloma XIV)

Study objectives

At R1:

That there is a difference in the proportion of patients, categorised as “unfit” or “frail” at trial

entry, requiring early cessation of treatment (within 60 days of randomisation) between standard up-front (reactive) or frailty score-adjusted (adaptive) dose modifications, with superiority of the frailty score-adjusted (adaptive) dose modifications anticipated. The null hypothesis is that there is no difference.

At R2:

That there is a difference in progression-free survival between lenalidomide + placebo (R) and lenalidomide + ixazomib (R + I) maintenance therapy with superiority of R + I maintenance therapy anticipated. The null hypothesis is that there is no difference.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 11/09/2019, North East – Tyne & Wear South Research Ethics Committee (NHSBT Newcastle Blood & Transplant Centre Holland Drive, Newcastle upon Tyne, NE2 4NQ, UK; +44(0) 207 1048084; nrescommittee.northeast-tyneandwearsouth@nhs.net), REC ref: 19/NE/0215

Primary study design

Interventional

Study design

Multicenter interventional placebo-controlled double-blind randomized controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Multiple myeloma

Interventions

All participants receive 12 cycles of induction treatment with ixazomib, lenalidomide and dexamethasone and are randomised on a 1:1 basis at trial entry to the use of frailty score-adjusted up-front dose reductions vs. standard up-front dosing followed by toxicity dependent reactive dose modifications during therapy.

Randomisation 1 will be completed using a computer generated minimisation algorithm that incorporates a random element to ensure that all arms are well balanced for specific participant characteristics, details of which will be required at randomisation.

Participants randomised to the frailty adjusted arm will undergo assessment for frailty according to the IMWG Frailty Index be categorised as fit, unfit or frail.

Following 12 cycles of induction treatment participants alive and progression-free undergo a second randomisation on a 1:1 basis to maintenance treatment with lenalidomide plus placebo versus lenalidomide plus ixazomib. Participants and their treating physicians will be blinded to maintenance allocation.

Randomisation 2 will be completed using a computer generated minimisation algorithm that incorporates a random element to ensure that all arms are well balanced for specific participant characteristics, details of which will be required at randomisation.

Ixazomib is an oral hard gelatin capsule that is taken orally.
Lenalidomide is a hard capsule that is taken orally.
Dexamethasone is a hard capsule that is taken orally.
The placebo is an oral hard gelatin capsule that is taken orally.

All participants will receive 12 cycles of induction treatment, each treatment cycle is 28 days in length.

Participants who are randomised to the standard up-front dosing followed by toxicity dependent dose-modifications (reactive) arm will receive:

4 mg of ixazomib on days 1, 8 and 15
25 mg of lenalidomide on days 1-21
40 mg of dexamethasone in participants ≤ 75 years or 20 mg dexamethasone in participants > 75 years on days 1, 8, 15, 22

Participants randomised to the frailty score-adjusted dosing arm (adaptive) and are categorised as FIT will receive:

4 mg of ixazomib on days 1, 8 and 15
25 mg of lenalidomide on days 1-21
40 mg of dexamethasone on days 1, 8, 15, 22

Participants randomised to the frailty score-adjusted dosing arm (adaptive) and are categorised as UNFIT will receive:

4 mg of ixazomib on days 1, 8 and 15
15 mg of lenalidomide on days 1-21
20 mg of dexamethasone on days 1, 8, 15, 22

Participants randomised to the frailty score-adjusted dosing arm (adaptive) and are categorised as FRAIL will receive:

4 mg of ixazomib on days 1, 8 and 15
10 mg of lenalidomide on days 1-21
10 mg of dexamethasone on days 1, 8, 15, 22

Participants who progress to maintenance and are randomised to receive lenalidomide and placebo will receive:

10 mg of lenalidomide on days 1-21
4 mg of placebo on days 1, 8, 15

Participants who progress to maintenance and are randomised to receive lenalidomide and placebo will receive:

10 mg of lenalidomide on days 1-21
4 mg of ixazomib on days 1, 8, 15

The duration of trial treatment for individual participants will vary, as treatment will continue until disease progression or intolerable toxicity. On average, it is expected that a participant will receive trial treatment for an average of 37 months: they will receive 12 cycles of IRD induction, followed by a median of 25 cycles of maintenance. All cycles last for 28 days.

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Ixazomib, lenalidomide, dexamethasone

Primary outcome(s)

Randomisation 1 (R1): Early treatment cessation (yes or no). Participants will be defined to have ceased treatment early if they die, progress, or are withdrawn from treatment (by a treating clinician) or withdraw consent for trial treatment, within 60 days of R1.

Randomisation 2 (R2): Progression-free survival (PFS-R2): time of first documented evidence of disease progression or death from any cause. Individuals who are lost to follow-up or progression-free at the time of analysis will be censored at their last known date to be alive and progression-free

Key secondary outcome(s)

Measured using eCRFs and patient records unless otherwise indicated:

1. Progression-free survival (PFS-R1): the time from R1 to the time of first documented evidence of disease progression or death from any cause. Disease progression is defined according to the IMWG Uniform Response Criteria for Multiple Myeloma
2. Time to progression: the time from randomisation to the date of first documented evidence of disease progression
3. Time to Progression-free survival two (PFS2): time from randomisation to the time of the second documented disease progression or death from any cause
4. Overall survival (OS): the time from randomisation to the time of death from any cause
5. Survival after progression: time from the date of first documented evidence of disease progression to the date of death from any cause
6. Death within 12 months of R1 (yes or no)
7. Overall response rate (ORR): whether a participant had sCR, CR, VGPR, PR, MR, SD or PD at the end of induction according to the IMWG Uniform Response Criteria for Multiple Myeloma
8. Attainment of $\geq$ VGPR (yes or no)
9. Attainment of Minimal Residual Disease (MRD) negativity (yes or no, according to the IMWG MRD criteria)
10. Duration of response (DoR): time from the first observation of response $\geq$ PR, following R1, to the time of first documented evidence of disease progression or death confirmed related to progression
11. Time to improved response: time from the date of R2 to the date the response category is first improved based on the Modified International Uniform Response Criteria for Multiple Myeloma
12. Time to next treatment: time from R1 to the start date of the next line of treatment (i.e. treatment following documented evidence of progressive disease) or death from any cause
13. Treatment compliance and total amount of therapy delivered:
 - 13.1. Did the participant receive 12 cycles of induction treatment (yes or no)
 - 13.2. Number of induction and maintenance cycles which the participant received. This may be extended to consider the percentage of protocol dose delivered. For each treatment (ixazomib, lenalidomide, dexamethasone) this will be defined as the total dose received in a cycle compared to the total dose the participant should have received in the cycle without modifications, averaged across all cycles of treatment
14. Toxicity and safety reported based on the adverse events, as graded by CTCAE V5 and determined by routine clinical assessments at each centre. The number of SAEs will be reported

according to MedDRA System Organ Class. All second primary malignancies will be reported based on information collected on the CRF

15. Quality of Life (QoL) using the patient-reported outcome measures; EORTC-QLQ-C30, EORTC-QLQ-MY20 and EQ-5D (3 Level) at R1, after cycles 2,6 and 12 during induction treatment. They are also collected after cycles 6 and 12 during maintenance treatment

16. Cost-effectiveness: cost per incremental QALY below £20,000 and/or a positive incremental net monetary benefit. For R1, the cost-effectiveness of standard dose IRD vs frailty adjusted dose IRD will be analysed. For R2, the cost-effectiveness of maintenance therapy using R vs R+I will be analysed

Added 07/07/2022:

17. Event-free survival (EFS) is measured from randomisation to the first instance of one of the following events; death, progression, discontinuation of the randomised treatment, a grade 4 haematological toxicity or a non-haematological toxicity $\geq$ grade 3

Completion date

31/08/2027

Eligibility

Key inclusion criteria

Inclusion criteria for Randomisation 1 (R1):

1. Newly diagnosed as having MM according to the updated IMWG diagnostic criteria 2014 requiring treatment
2. Not eligible for stem cell transplant
3. Aged at least 18 years
4. Meet all of the following blood criteria within 14 days before R1:
 - 4.1. Haematological:
 - 4.1.1. Absolute neutrophil count (ANC) $\geq 1 \times 10^9/\text{l}$. Unless the participant has a known /suspected diagnosis of familial or racial neutropenia in which case an ANC $\geq 0.75 \times 10^9/\text{l}$ is allowed. The use of growth factor support is permitted
 - 4.1.2. Platelet count $\geq 50 \times 10^9/\text{l}$, or, in the case of heavy bone marrow infiltration ($\geq 50\%$) which in the opinion of the investigator is the cause of the thrombocytopenia and provided appropriate supportive measures and patient monitoring are in place, platelet count $\geq 30 \times 10^9/\text{l}$ is permitted. Please note: Platelet transfusions are not allowed ≤ 3 days prior to randomisation in order to meet these values
 - 4.1.3. Haemoglobin $\geq 80 \text{ g/l}$. The use of red blood cell transfusions is permitted
 - 4.2. Biochemical:
 - 4.2.1. Total bilirubin $\leq 3 \times$ upper limit of normal (ULN)
 - 4.2.2. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) $\leq 3 \times$ ULN
5. Meet the pregnancy prevention requirements
6. Able to provide written informed consent

Inclusion criteria for Randomisation 2 (R2):

1. Randomised into the FiTNess (Myeloma XIV) trial and received induction chemotherapy with ixazomib and lenalidomide continued for 12 cycles
2. Achieved at least MR at the end of IRD induction according to the IMWG Uniform Response Criteria for Multiple Myeloma, with no evidence of progression prior to R2
3. Meet all of the following blood criteria within 14 days before R2:
 - 3.1. Haematological:
 - 3.1.1. Absolute neutrophil count (ANC) $\geq 1 \times 10^9/\text{l}$. Unless the participant has a known

/suspected diagnosis of familial or racial neutropenia in which case an ANC $\geq 0.75 \times 10^9/l$ is allowed. The use of growth factor support is permitted

3.1.2. Platelet count $\geq 50 \times 10^9/l$. Please note: Platelet transfusions are not allowed ≤ 3 days prior to randomisation in order to meet these values

3.1.3. Haemoglobin ≥ 80 g/l. The use of red blood cell transfusions is permitted

3.2. Biochemical:

3.2.1. Total bilirubin $\leq 3 \times$ upper limit of normal (ULN)

3.2.2. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) $\leq 3 \times$ ULN

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Total final enrolment

733

Key exclusion criteria

Exclusion criteria at R1:

1. Smouldering MM, MGUS, solitary plasmacytoma of bone, or extramedullary plasmacytoma (without evidence of MM)
2. Received previous treatment for MM, with the exception of local radiotherapy to relieve bone pain or spinal cord compression, prior bisphosphonate treatment, or corticosteroids as long as the total dose does not exceed the equivalent of 160 mg dexamethasone
3. Known resistance, intolerance or sensitivity to any component of the planned therapies
4. Prior or concurrent invasive malignancies except the following:
 - 4.1. Adequately treated basal cell or squamous cell skin cancer
 - 4.2. Incidental finding of low grade (Gleason 3+3 or less) prostate cancer requiring no intervention
 - 4.3. Adequately treated carcinoma in situ of the breast or cervix no longer requiring medical or surgical intervention
 - 4.4. Any cancer from which the subject has been disease-free for at least 3 years
5. Pregnant, lactating or breastfeeding female participants
6. Major surgery within 14 days before randomisation. This would include surgical intervention for relief of cord compression but does not include vertebroplasty or kyphoplasty
7. Systemic treatment, within 14 days before the first dose of ixazomib with strong CYP3A inducers (e.g. rifampicin, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of St John's wort
8. Any concomitant drug therapy which, in the opinion of the investigator, may lead to an unacceptable interaction with any of the agents ixazomib, lenalidomide, dexamethasone, and that cannot be safely stopped prior to trial entry. Full details of interactions can be found in the

SPCs

9. Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of trial treatment, including difficulty swallowing
10. $\geq$ Grade 2 peripheral neuropathy
11. Known HIV positive
12. Participant has current or prior hepatitis B surface antigen-positive or hepatitis C antibody positive. Participants must have screening conducted within 14 days before R1
13. Active systemic infection
14. Any other medical or psychiatric condition which, in the opinion of the investigator, contraindicates the participant's participation in this study
15. Receipt of live vaccination within 30 days prior to R1

Exclusion criteria for R2:

1. Received any anti-myeloma therapy other than their randomised trial treatment, with the exception of local radiotherapy to relieve bone pain (in the absence of disease progression), or bisphosphonate treatment
2. SD or disease progression according to the IMWG Uniform Response Criteria for Multiple Myeloma (see Appendix 2)
3. Known resistance, intolerance or sensitivity to ixazomib or lenalidomide that required cessation of either agent during induction
4. Developed any malignancy since R1 except the following:
 - 4.1. Adequately treated basal cell or squamous cell skin cancer
 - 4.2. Incidental finding of low grade (Gleason 3+3 or less) prostate cancer requiring no intervention
 - 4.3. Adequately treated carcinoma in situ of the breast or cervix no longer requiring medical or surgical intervention
5. Pregnant, lactating or breastfeeding female participants
6. Major surgery within 14 days before randomisation. This does not include vertebroplasty or kyphoplasty
7. Systemic treatment, within 14 days before the first dose of ixazomib with strong CYP3A inducers (e.g. rifampicin, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of St John's wort
8. Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of trial treatment, including difficulty swallowing
9. $\geq$ Grade 2 peripheral neuropathy, or grade 1 with pain
10. Known HIV positive
11. Current or known hepatitis B surface antigen positive or hepatitis C antibody positive
12. Active systemic infection
13. Any other medical or psychiatric condition which, in the opinion of the investigator, contraindicates the participant's continued participation in this study
14. Receipt of live vaccination within 30 days prior to R1 or receipt of live vaccination at any point during the trial prior to R2

Date of first enrolment

04/08/2020

Date of final enrolment

04/02/2024

Locations

Countries of recruitment

United Kingdom

England

Scotland

Wales

Study participating centre**Royal Devon & Exeter Hospital**

Barrack Road Devon

Exeter

United Kingdom

EX2 5DW

Study participating centre**Cheltenham Hospital**

Sandford Road

Cheltenham

United Kingdom

GL53 7AN

Study participating centre**James Cook University Hospital**

Marlon Road

Middlesbrough

United Kingdom

TS4 3BW

Study participating centre**Singleton Hospital**

Sketty Lane

Swansea

United Kingdom

SA2 8QA

Study participating centre**Queen's Hospital Romford**

Haematology & Oncology Department Queens Hospital

Rom Valley Way

Romford
United Kingdom
RM7 0AG

Study participating centre
Huddersfield Royal Infirmary
Acre Street
Lindley
Huddersfield
United Kingdom
HD3 3EA

Study participating centre
Calderdale Royal Hospital
Halifax
United Kingdom
HX3 0PW

Study participating centre
Sunderland Royal Hospital
Kayll Road
Sunderland
United Kingdom
SR4 7TP

Study participating centre
South Tyneside Hospital
Harton Lane
South Shields
United Kingdom
NE34 0PL

Study participating centre
Kent and Canterbury Hospital
Ethelbert Road
Canterbury
United Kingdom
CT1 3NG

Study participating centre

William Harvey Hospital

Kennington Road
Willesborough
Ashford
United Kingdom
TN24 0LZ

Study participating centre

Queen Elizabeth Hospital the Queen Mother

St Peters Road
Margate
United Kingdom
CT9 4AN

Study participating centre

Colchester Hospital

Turner Road
Colchester
United Kingdom
CO4 5JL

Study participating centre

Gloucestershire Royal Hospital

Great Western Road
Gloucester
United Kingdom
GL1 3NN

Study participating centre

Kettering General Hospital

Rothwell Road
Kettering
United Kingdom
NN16 8UZ

Study participating centre

Kings College Hospital

Denmark Hill

London
United Kingdom
SE5 9RS

Study participating centre
Princess Royal University Hospital
Farnborough Common
Orpington
United Kingdom
BR6 8ND

Study participating centre
Blackpool Victoria Hospital
Whinney Heys Road
Blackpool
United Kingdom
FY3 8NR

Study participating centre
Trafford General Hospital
Moorside Road
Davyhulme
Manchester
United Kingdom
M41 5SL

Study participating centre
Manchester Royal Infirmary
Oxford Road
Manchester
United Kingdom
M13 9WL

Study participating centre
Wythenshaw Hospital
Southmoor Road
Wythenshaw
Manchester
United Kingdom
M23 9LT

Study participating centre
Freeman Hospital
High Heaton Tyne and Wear
Newcastle Upon Tyne
United Kingdom
NE7 7DN

Study participating centre
Aberdeen Royal Infirmary
Foresterhill Road
Aberdeen
United Kingdom
AB25 2ZN

Study participating centre
Ninewells Hospital
Dundee
United Kingdom
DD1 9SY

Study participating centre
Norfolk & Norwich University Hospital
Colney Lane
Norwich
United Kingdom
NR4 7UY

Study participating centre
Southmead Hospital
Bristol
United Kingdom
BS10 5NB

Study participating centre
Peterborough City Hospital
Edith Cavell Campus
Bretton Gate

Peterborough
United Kingdom
PE3 9GZ

Study participating centre
Hinchingbrooke Hospital
Huntingdon
United Kingdom
PE29 6NT

Study participating centre
Nottingham City Hospital
Hucknall Road
Nottingham
United Kingdom
NG5 1PB

Study participating centre
Royal Berkshire Hospital
London Road
Reading
United Kingdom
RG1 5AN

Study participating centre
Royal Bournemouth Hospital
Castle Lane East
Bournemouth
United Kingdom
BH7 7DW

Study participating centre
Friarage Hospital
Northallerton
United Kingdom
DL6 1JG

Study participating centre

St George's Hospital
Blackshaw Road
London
United Kingdom
SW17 0QT

Study participating centre
St Helens Hospital
Marshalls Cross Road
St. Helens
United Kingdom
WA9 3DA

Study participating centre
Whiston Hospital
Warrington Road
Prescot
United Kingdom
L35 5DR

Study participating centre
Torbay Hospital
Lowes Bridge
Torquay
United Kingdom
TQ2 7AA

Study participating centre
Bristol Haematology & Oncology Centre
Bristol Royal Infirmary
King Edward Yard
Marlborough Hill
Bristol
United Kingdom
BS2 8HW

Study participating centre
Royal Derby Hospital
Uttoxeter Road

Derbym
United Kingdom
DE22 3NE

Study participating centre
University College London Hospital
235 Euston Road
London
United Kingdom
NW1 2BU

Study participating centre
Royal Albert Edward Infirmary
Wigan Lane
Wigan
United Kingdom
WN1 2NN

Study participating centre
Leicester Royal Infirmary
Aylestone Road
Leicester
United Kingdom
LE2 7LG

Study participating centre
Derriford Hospital
Derriford Road
Crownhill
Plymouth
United Kingdom
PL6 8DH

Study participating centre
Worthing Hospital
Lyndhurst Road
Worthing
United Kingdom
BN11 2DH

Study participating centre
St Richards Hospital
Spitafield Lane
Chichester
United Kingdom
PO19 6SE

Study participating centre
The County Hospital
Stonebow
Road Hereford
United Kingdom
HR1 2BN

Sponsor information

Organisation
University of Leeds

Funder(s)

Funder type
Charity

Funder Name
Cancer Research UK

Alternative Name(s)
CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type
Private sector organisation

Funding Body Subtype
Other non-profit organizations

Location
United Kingdom

Funder Name

Takeda Pharmaceuticals International

Alternative Name(s)

Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals International GmbH

Funding Body Type

Private sector organisation

Funding Body Subtype

For-profit companies (industry)

Location

Switzerland

Funder Name

Celgene

Alternative Name(s)

Celgene Corporation

Funding Body Type

Private sector organisation

Funding Body Subtype

For-profit companies (industry)

Location

United States of America

Results and Publications

Individual participant data (IPD) sharing plan

De-identified individual participant data datasets generated and/or analysed during the current study will be available upon request from the Clinical Trials Research Unit, University of Leeds (contact CTRU-DataAccess@leeds.ac.uk in the first instance). Data will be made available at the end of the trial, i.e. usually when all primary and secondary endpoints have been met and all key analyses are complete. Data will remain available from then on for as long as CTRU retains the data.

CTRU makes data available by a 'controlled access' approach. Data will only be released for legitimate secondary research purposes, where the Chief Investigator, Sponsor and CTRU agree that the proposed use has scientific value and will be carried out to a high standard (in terms of scientific rigour and information governance and security), and that there are resources available to satisfy the request. Data will only be released in line with participants' consent, all applicable laws relating to data protection and confidentiality, and any contractual obligations to which the CTRU is subject. No individual participant data will be released before an

appropriate agreement is in place setting out the conditions of release. The agreement will govern data retention, usually stipulating that data recipients must delete their copy of the released data at the end of the planned project.

The CTRU encourages a collaborative approach to data sharing and believes it is best practice for researchers who generated datasets to be involved in subsequent uses of those datasets. Recipients of trial data for secondary research will also receive data dictionaries, copies of key trial documents and any other information required to understand and reuse the released datasets.

The conditions of release for aggregate data may differ from those applying to individual participant data. Requests for aggregate data should also be sent to the above email address to discuss and agree on suitable requirements for release.

IPD sharing plan summary
Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article		02/06/2022	08/06/2022	Yes	No
HRA research summary			28/06/2023	No	No